InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.770 0.02 (2.53%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$210 Investor Update 31 Oct 2018 10:02AM $0.235 $0.770 risen by 227.66%
$210 Orthocell Secures CelGro Patent Protection in Japan 23 Oct 2018 9:38AM $0.225 $0.770 risen by 242.22%
$210 Notice of Annual General Meeting/Proxy Form 19 Oct 2018 6:13PM $0.240 $0.770 risen by 220.83%
$210 Successful CelGro Results Presented at Key Euro Conference 18 Oct 2018 9:49AM $0.240 $0.770 risen by 220.83%
$210 Appendix 4G 17 Oct 2018 2:24PM $0.240 $0.770 risen by 220.83%
$210 Annual Report to shareholders 17 Oct 2018 2:23PM $0.240 $0.770 risen by 220.83%
$210 Orthocell Receives A$2.5m R&D tax Incentive Refund 11 Oct 2018 9:44AM $0.250 $0.770 risen by 208%
$210 CelGro Used as Artificial Periosteum Repairs Bone 4 Oct 2018 9:17AM $0.260 $0.770 risen by 196.15%
$210 Appendix 3B 4 Oct 2018 9:12AM $0.260 $0.770 risen by 196.15%
$210 CelGro used in Nano Medicine Breakthrough 27 Sep 2018 9:57AM $0.280 $0.770 risen by 175%
$210 Preliminary Final Report and Annual Financial Statements 31 Aug 2018 6:27PM $0.295 $0.770 risen by 161.02%
$210 Appendix 4C - Quarterly 31 Jul 2018 7:07PM $0.340 $0.770 risen by 126.47%
$210 OCC Reports First Product Use and Sales of CelGro in Ireland 26 Jul 2018 9:53AM $0.330 $0.770 risen by 133.33%
$210 CelGro Pre-Submission Meeting Completed with the FDA 24 Jul 2018 9:47AM $0.330 $0.770 risen by 133.33%
$210 Orthocell Receives New Patent for Celgro Platform Technology 20 Jul 2018 10:28AM $0.305 $0.770 risen by 152.46%
$210 OCC Reports First Product Use and Sales of Celgro in Italy 17 Jul 2018 9:33AM $0.300 $0.770 risen by 156.67%
$210 Orthocell Appoints Exclusive Distributor in the UK 10 Jul 2018 8:55AM $0.310 $0.770 risen by 148.39%
$210 New CelGro Arthroscopic Tendon Regeneration Study Commences 2 Jul 2018 8:24AM n/a $0.770 n/a
$210 Dr. Jonathan Bell Appointed to Orthocell Advisory Board 25 Jun 2018 9:43AM $0.345 $0.770 risen by 123.19%
$210 Orthocell Announces Successful Ortho-ATI Study Results 14 Jun 2018 9:31AM $0.350 $0.770 risen by 120%
$210 Orthocell Announces Successful Tendon Study Results 6 Jun 2018 9:54AM $0.350 $0.770 risen by 120%
$210 First Product Use and Sales of CelGro in Poland 31 May 2018 9:30AM $0.355 $0.770 risen by 116.90%
$210 Orthocell Secures CelGro Patent Protection in Europe 24 May 2018 10:15AM $0.355 $0.770 risen by 116.90%
$210 First Product Use and Sale of CelGro in Europe 22 May 2018 9:36AM $0.355 $0.770 risen by 116.90%
$210 10th Patient Treatment Milestone in Human Tendon Study 17 May 2018 9:56AM $0.350 $0.770 risen by 120%

551 - 575 of 762 results

Page 23 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.